Stay updated on T-DXd in HER2 Expressing Tumors Clinical Trial
Sign up to get notified when there's something new on the T-DXd in HER2 Expressing Tumors Clinical Trial page.

Latest updates to the T-DXd in HER2 Expressing Tumors Clinical Trial page
- Check3 days agoChange DetectedThe revision tag at the bottom of the page updated from v3.6.2 to v3.6.3, indicating a new page release or update rather than a change to study details. This is a metadata-level update and does not alter the study content.SummaryDifference0.0%

- Check10 days agoChange DetectedThe page's revision tag was updated to v3.6.2, replacing v3.6.0, indicating a backend/template update without changes to the study details.SummaryDifference0.0%

- Check17 days agoChange DetectedA new publication citation related to DESTINY-PanTumor02 was added to Publications, including the authors, journal, DOI, and Epub date; the Online ahead of print note for that citation was removed.SummaryDifference0.0%

- Check24 days agoChange DetectedEnrollment status updated to indicate recruitment is closed, and new user guidance sections were added (How to Read a Study Record, Common Questions, How to Join a Study). The page also shows a revision to v3.6.0 and a removal of the Intervention/Treatment label, reflecting content restructuring.SummaryDifference0.2%

- Check31 days agoChange DetectedFooter revision tag updated from v3.5.4 to v3.5.5, indicating a page patch has been applied. This reflects an internal versioning update rather than a change to the study content or user-facing features.SummaryDifference0.0%

- Check46 days agoChange DetectedA new PubMed citation has been added to Publications for DESTINY-PanTumor02, describing antitumor activity and biomarker analyses in HER2-expressing gynecologic cancers. This expands the study's related literature tied to the trial without changing any study details.SummaryDifference0.0%

Stay in the know with updates to T-DXd in HER2 Expressing Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the T-DXd in HER2 Expressing Tumors Clinical Trial page.